Xellar Biosystems

Xellar Biosystems (耀速科技) is a next-generation AI-driven organ-on-chip platform company working at the intersection of 3D biological intelligence and drug discovery. It has secured multiple funding rounds including a Series A of over RMB 200 million and an earlier angel round from ZhenFund, which remains an active backer . The company has gained notable regulatory and industry traction: its organ-chip platform began collaborating with the FDA and 3Rs organizations in 2023, and as of January 2026 entered the FDA's Innovation Science and Technology Advancement Program review pathway, positioning it to potentially become among the first drug development tools globally to receive FDA scientific qualification . In research partnerships, Xellar co-published a major scientific result with Pfizer in mid-2025 , and prior to that had work featured across two Nature sub-journals in January 2025 . Its positioning centers on using AI and 3D biology to redefine preclinical drug evaluation, with an explicit eye toward global regulatory recognition.